The Immune Checkpoint Inhibitor Landscape: Where We Are in 2019
April 30, 2019–April 30, 2020
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grants from Bristol-Myers Squibb.
- Appraise current and emerging immuno-oncology agents and their roles in various cancer types
- Describe the biomarkers being examined to predict response to immunotherapy
- Assess emerging data concerning the safety and efficacy of different treatment combinations with immunotherapies in the treatment of oncologic disease states
- Formulate effective strategies to manage patient adherence and unique adverse events in both monotherapy and combination therapies
This accredited activity has been designed for oncology pharmacists and other pharmacists who manage or interact with people with cancer.
This message is being sent by HOPA on behalf of an external organization. HOPA does not endorse any information or recommendations contained herein nor does it verify the accuracy of the content of this third-party communication. The information presented in this message is not meant to serve as a guideline for patient management. Any procedures, medications, or other course of diagnosis or treatment discussed or suggested should not be used by clinicians without evaluation of their patients' conditions and consideration of possible contraindications. Please review any applicable manufacturer's product information.